Kathy V. Turner's most recent trade in Elanco Animal Health Inc was a trade of 13,838 Common Stock done . Disclosure was reported to the exchange on Nov. 29, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health Inc | Kathy V. Turner | Director | 29 Nov 2024 | 13,838 | 13,838 (0%) | 0% | 0 | Common Stock | ||
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Grant, award, or other acquisition of securities at price $ 79.54 per share. | 15 Feb 2023 | 1,000 | 8,379 (0%) | 0% | 79.5 | 79,540 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 510.03 per share. | 15 Feb 2023 | 1,000 | 7,379 (0%) | 0% | 510.0 | 510,031 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 1,000 | 3,736 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.50 per share. | 15 Feb 2023 | 10 | 7,389 (0%) | 0% | 79.5 | 795 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 515.60 per share. | 15 Feb 2023 | 10 | 7,379 (0%) | 0% | 515.6 | 5,156 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 10 | 3,726 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.54 per share. | 14 Feb 2023 | 2,000 | 9,379 (0%) | 0% | 79.5 | 159,080 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 2,000 | 4,736 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 505.06 per share. | 14 Feb 2023 | 1,000 | 8,379 (0%) | 0% | 505.1 | 505,059 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 504.09 per share. | 14 Feb 2023 | 577 | 7,489 (0%) | 0% | 504.1 | 290,861 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 504.66 per share. | 14 Feb 2023 | 313 | 8,066 (0%) | 0% | 504.7 | 157,959 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 503.65 per share. | 14 Feb 2023 | 293 | 7,379 (0%) | 0% | 503.6 | 147,569 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 210 | 1,315 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 210 | 7,150 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 181 | 7,331 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 181 | 1,134 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 162 | 7,439 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 162 | 972 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 502.82 per share. | 14 Feb 2023 | 110 | 7,379 (0%) | 0% | 502.8 | 55,310 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 93 | 7,672 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 93 | 793 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 86 | 7,579 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2023 | 86 | 886 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 505.04 per share. | 09 Feb 2023 | 1,000 | 6,940 (0%) | 0% | 505.0 | 505,037 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 1,000 | 6,736 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.54 per share. | 09 Feb 2023 | 1,000 | 7,940 (0%) | 0% | 79.5 | 79,540 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 141.60 per share. | 01 Dec 2022 | 3,000 | 9,923 (0%) | 0% | 141.6 | 424,800 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 436.00 per share. | 01 Dec 2022 | 3,000 | 6,923 (0%) | 0% | 436 | 1,308,000 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 3,000 | 7,386 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2022 | 8,567 | 1,581 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 178.26 per share. | 10 Nov 2022 | 8,567 | 15,490 (0%) | 0% | 178.3 | 1,527,153 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 206.94 per share. | 10 Nov 2022 | 5,310 | 12,233 (0%) | 0% | 206.9 | 1,098,851 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2022 | 5,310 | 3,056 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 436.06 per share. | 10 Nov 2022 | 3,000 | 6,923 (0%) | 0% | 436.1 | 1,308,187 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 438.00 per share. | 10 Nov 2022 | 3,000 | 9,923 (0%) | 0% | 438 | 1,314,000 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 410.02 per share. | 10 Nov 2022 | 2,655 | 9,578 (0%) | 0% | 410.0 | 1,088,596 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 405.21 per share. | 10 Nov 2022 | 2,630 | 6,923 (0%) | 0% | 405.2 | 1,065,710 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 442.05 per share. | 10 Nov 2022 | 2,567 | 12,293 (0%) | 0% | 442.0 | 1,134,734 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 406.12 per share. | 10 Nov 2022 | 25 | 9,553 (0%) | 0% | 406.1 | 10,153 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.85 per share. | 18 Feb 2022 | 1,474 | 6,180 (0%) | 0% | 67.9 | 100,011 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 1,474 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 141.60 per share. | 18 Feb 2022 | 706 | 6,886 (0%) | 0% | 141.6 | 99,970 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 706 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 3,078 | 3,078 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 371 | 2,376 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 505.53 per share. | 14 Feb 2022 | 295 | 4,706 (0%) | 0% | 505.5 | 149,131 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 211 | 4,361 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 211 | 2,165 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 210 | 4,571 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 210 | 1,955 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 197 | 197 | - | - | Incentive Stock Option (right-to-buy) | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 181 | 4,752 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 181 | 1,774 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 162 | 4,914 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 162 | 1,612 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 87 | 1,525 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2022 | 87 | 5,001 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2021 | 1,256 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.54 per share. | 31 Aug 2021 | 1,256 | 4,131 (0%) | 0% | 79.5 | 99,902 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2021 | 2,250 | 7,736 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.54 per share. | 27 Aug 2021 | 2,250 | 5,125 (0%) | 0% | 79.5 | 178,965 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 689.00 per share. | 27 Aug 2021 | 1,250 | 2,875 (0%) | 0% | 689 | 861,250 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 685.00 per share. | 27 Aug 2021 | 1,000 | 4,125 (0%) | 0% | 685 | 685,000 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2021 | 276 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 678.00 per share. | 27 Aug 2021 | 276 | 2,875 (0%) | 0% | 678 | 187,128 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 64.24 per share. | 27 Aug 2021 | 276 | 3,151 (0%) | 0% | 64.2 | 17,730 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 558.44 per share. | 28 May 2021 | 2,000 | 2,866 (0%) | 0% | 558.4 | 1,116,884 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 545.00 per share. | 24 May 2021 | 2,000 | 4,866 (0%) | 0% | 545 | 1,090,000 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 549.00 per share. | 24 May 2021 | 900 | 6,866 (0%) | 0% | 549 | 494,100 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 540.00 per share. | 20 May 2021 | 1,000 | 8,766 (0%) | 0% | 540 | 540,000 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 545.00 per share. | 20 May 2021 | 1,000 | 7,766 (0%) | 0% | 545 | 545,000 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Sale of securities on an exchange or to another person at price $ 535.00 per share. | 20 May 2021 | 1,000 | 9,766 (0%) | 0% | 535 | 535,000 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2021 | 3,131 | 3,131 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 544.08 per share. | 14 Feb 2021 | 388 | 10,754 (0%) | 0% | 544.1 | 211,103 | Common Stock |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2021 | 345 | 2,992 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 221 | 10,376 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 221 | 2,771 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 212 | 10,588 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 212 | 2,559 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 210 | 10,798 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 210 | 2,349 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2021 | 183 | 183 | - | - | Incentive Stock Option (right-to-buy) | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 181 | 10,979 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 181 | 2,168 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 163 | 11,142 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Kathy V. Turner | Senior Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 163 | 2,005 | - | - | Restricted Stock Unit |